Safety of AADC Gene Therapy for Moderately Advanced Parkinson Disease: Three-Year Outcomes From the PD-1101 Trial

BACKGROUND AND OBJECTIVES: To report final, 36-month safety and clinical outcomes from the PD-1101 trial of NBIb-1817 (VY-AADC01) in participants with moderately advanced Parkinson disease (PD) and motor fluctuations. METHODS: PD-1101 was a phase 1b, open-label, dose escalation trial of VY-AADC01, a...

Descripción completa

Detalles Bibliográficos
Autores principales: Christine, Chadwick W., Richardson, R. Mark, Van Laar, Amber D., Thompson, Marin E., Fine, Elisabeth M., Khwaja, Omar S., Li, Chunming, Liang, Grace S., Meier, Andreas, Roberts, Eiry W., Pfau, Madeline L., Rodman, Josh R., Bankiewicz, Krystof S., Larson, Paul S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8726573/
https://www.ncbi.nlm.nih.gov/pubmed/34649873
http://dx.doi.org/10.1212/WNL.0000000000012952

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8726573/
https://www.ncbi.nlm.nih.gov/pubmed/34649873
http://dx.doi.org/10.1212/WNL.0000000000012952

Ejemplares similares